Rigel Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It operates as a clinical-stage biopharmaceutical firm, specializing in targeted drugs within the therapeutic areas of immunology, oncology, and immune oncology. The company's pipeline includes programs targeting IRAK1/4 inhibitors and RIPK1 inhibitors, alongside partnered programs and investigator-sponsored research. Rigel Pharmaceuticals, Inc. emphasizes clinical trials and expanded access policies to advance its product candidates. Its products address unmet needs in hematologic conditions and oncology, positioning it as a key player in specialized biopharma markets serving patients and healthcare providers. Founded in 1996 and headquartered in South San Francisco, California, Rigel Pharmaceuticals, Inc. continues to drive innovation in precision medicine for immune-mediated and cancerous diseases.